Ronald Li

Ronald Li has a diverse work experience spanning multiple industries. Ronald is currently serving as the Chief Executive Officer at Medera Biopharmaceutical. Prior to that, they held the position of Chief Scientific Officer at Sardocor. In 2018, they founded Xellera Therapeutics and served as the Executive Director. Ronald also held the roles of CEO and Interim Chief Research and Development Officer at Novoheart. Additionally, Ronald Li has contributed to academia as a Court Member at The Hong Kong Polytechnic University and held various professorial and directorial positions at The University of Hong Kong, Karolinska Institutet, and University of California, Davis. Ronald has also conducted research at the Icahn School of Medicine at Mount Sinai and was an Associate Investigator at Shriners Hospital For Children.

Ronald Li completed their education in a chronological order. Ronald attended Diocesan Boys School in Hong Kong from 1983 to 1989, although no degree or specific field of study was mentioned during this time. Ronald then pursued a Bachelor of Science degree with Honors (BS (Hons)) in Biochemistry with a Biotechnology Option at the University of Waterloo from 1990 to 1994. Subsequently, they enrolled in the University of Toronto from 1995 to 1998 to obtain their Doctor of Philosophy (PhD) in Physiology with a specialization in Cardiology. Finally, Ronald Li completed a post-doctoral fellowship in Cardiac Electrophysiology at The Johns Hopkins University School of Medicine from 1998 to 2001.